Learn more about our programs
Multiple Myeloma

Novel Treatment for Relapsed/Refractory Multiple Myeloma: A Focus on Bispecific Antibodies

Now Available On Demand

Watch Now

Produced in collaboration with BlackDoctor.org and LLS Myeloma Link.
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.


  • Impact of multiple myeloma (MM) on racial and ethnic groups
  • New therapies and clinical trials
  • Bispecific antibodies
  • Symptom changes and quality of life
  • Types of treatment for relapsed/refractory multiple myeloma (RRMM)
  • Patient stories and resources

There is a need for new MM treatments, particularly for patients who have relapsing MM after double- and/or triple-combination therapy. The latest research has provided new treatment options, such as bispecific antibodies, that show promise after multiple therapies. To achieve equitable care, patients and caregivers must be open to sharing preferences with their care team when discussing the treatment options.

Join an expert panel featuring a hematologist/oncologist, a nurse practitioner, and a patient advocate for a discussion of significant differences in clinical presentations with MM and inequities in the treatment of MM patients. The panel will also review the mechanisms of action (MOAs) of new agents and current research that demonstrates promise in treating RRMM. Panelists will also share ideas to help you talk to your healthcare team about your treatment choices and determine if a clinical trial might be an option for you.

Sign up to watch on-demand.




Cleveland Clinic Taussig Cancer Institute Department of Hematology and Medical Oncology
Member, Population and Cancer Prevention Program, Case Comprehensive Cancer Center

Attaya Suvannasankha

Associate Professor of Clinical Medicine
Indiana University School of Medicine

Lynne Steele, LSW, OSW-C

Senior Information Specialist, Information Resource Center
The Leukemia & Lymphoma Society

Clinical Trials Finder




  • BDO logo
  • LLS logo